Legislation Quick Search
12/05/2023 10:43 AM
Pennsylvania House of Representatives
Home / House Co-Sponsorship Memoranda

House Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search

House of Representatives
Session of 2017 - 2018 Regular Session


Posted: July 7, 2017 04:39 PM
From: Representative Mark Rozzi
To: All House members
Subject: Adding Naltrexone to the Achieving Better Care by Monitoring All Prescriptions Program (ABC-MAP) Act.
In the near future, I plan to introduce legislation to include naltrexone, which is used to treat opioid disorders and alcohol use, in the Achieving Better Care by Monitoring All Prescriptions Program (ABC-MAP) Act of 2014 (P.L.2911, No.191).

This proposal will add naltrexone to the definition of controlled substance under the act. While I understand that naltrexone is not a controlled substance, it is imperative that naltrexone is captured under the act as its combined use with opioids may be life-threatening.

The Substance Abuse and Mental Health Services Administration explains that if patients who are treated with naltrexone relapse after a period of abstinence, it is possible that the dosage of opioid that was previously used may result in respiratory arrest and circulatory collapse.

After meeting with specialists in my district, I feel that the inclusion of naltrexone in ABC-MAP is necessary in assessing a patient's situation. Therefore, in an effort to protect patients, I urge your support and co-sponsorship.

Introduced as HB2047